TAT 2012 in Amsterdam, The Netherlands, will be the tenth meeting in the series "International Congress on Targeted Anticancer Therapies". TAT 2012 will be another official ESMO Partnership Meeting, offered by the Amsterdam-based NDDO Education Foundation, and co-sponsored by the U.S. National Cancer Institute - Center for Cancer Research.

TAT meetings are characterized by their focus on targeted cancer therapeutics, in particular the most promising ones in the late preclinical and early clinical development stages. TAT 2012 will offer excellent opportunities for the presentation and discussion of ongoing and completed phase 1 studies in a highly interactive setting. Apart from being of importance to everyone involved in anticancer drug development on a daily basis, the TAT 2012 program will be of high educational value to oncologists wishing to stay abreast of emerging new treatment options.

Distinguishing features of TAT 2012:
• Focused on early phase development of promising targeted agents for cancer therapy
• Medium-sized event, creating excellent possibilities for personal interactions with colleagues
• Participants from academia and industry
• No paralllel sessions, avoiding the need to make difficult choices
• Attention to methodological and regulatory issues in new drug development
• Ample opportunity to present your own work in front of an international expert audience

Amsterdam as the venue of TAT 2012 hardly needs any further introduction. For TAT 2012, the congress series returns to its city of origin, a place well known to many who attended previous NDDO new drug meetings.

Location